Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US-Reference-Cited by-同舟云学术

Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US

Published:2017-11-30 Issue:2 Volume:34 Page:353-360
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Franklin Meg¹,Burns Leah²,Perez Samuel³,Yerragolam Deepak⁴,Makenbaeva Dinara⁵

Affiliation:

1. Franklin Pharmaceutical Consulting LLC, Rock Hill, SC, USA;

2. Center for Observational Research and Data Sciences, Princeton, NJ, USA;

3. Mu Sigma, Northbrook, IL, USA;

4. Mu Sigma Business Solutions, Karnataka, India;

5. Bristol-Myers Squibb Company, Princeton, NJ, USA

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1399870

Reference18 articles.

1. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

3. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

4. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

5. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia;Internal Medicine;2024

2. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors;PLOS ONE;2023-11-20

3. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study;The Oncologist;2023-08-10

4. Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio;Nigerian Journal of Clinical Practice;2023-06

5. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies;Frontiers in Oncology;2023-02-06